Navigation Links
FLU OIA Test

ProductsFLU OIA Test
Company Biostar
Item FLU OIA Test
Features 
  • Simple test procedure
  • No additional equipment required
  • The only rapid flu test with performance equivalent to 14-day viral culture
  • Description The FLU OIA test is a high performance assay for the undifferentiated rapid diagnosis of Influenza A and B with a simple, easy-to-use test that provides an answer in just over 15 minutes. Assay advantages include superior performance with mucoid samples, specimen flexibility, and performance equivalent to 14-day viral culture enables you to decrease costs for unnecessary ancillary testing, improve appropriate treatment, and decrease patient wait times.
    Info Biostar
    Customer Service: 800 637 3717

    Related medicine products :

    1. The Acceava Mononucleosis test
    2. Acceava MONO
    3. Acceava H.pylori
    4. The Acceava Trichomonas Rapid Test
    5. BioStar Acceava hCG Basic
    6. BioStar Acceava hCG Combo
    7. Antibiotic Antimycotic Solution: 10,000 I.U. Penicillin, 10,000 g/mL Streptomycin, 25 g/mL Amphotericin B
    8. Penicillin Streptomycin Solution: 5,000 I.U. Penicillin, 5,000 g/mL Streptomycin
    9. Gibco Penicillin-Streptomycin liquid
    10. Penicillin-Streptomycin
    11. Gibco Penicillin-Streptomycin-Glutamine (100X) liquid
    TAG: FLU OIA Test
    Other Medicine News:Health News:Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoint's NextRx Subsidiaries 2Health News:CVS/pharmacy Introduces New Coupon Center on CVS.com 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 3Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 4Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 5Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 2Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 3Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 4Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 5Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 7Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 8Health News:iUniverse Hosts Canadian Storytellers, Cystic Fibrosis Awareness Advocate for BookExpo America 2009 Book Signings 2Health News:New Website, ElasticBandageStore.com, Offers Elastic Bandages at Wholesale Prices 2
    Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 1Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 2MUSC Researchers Concerned About Online Drug Availability 57128 1MUSC Researchers Concerned About Online Drug Availability 57128 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 57123 1